ClinicalTrials.gg
CompletedNCT06586112ONWARD1Updated Oct 28, 2026

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis

A Phase 3 interventional study of Envudeucitinib and Apremilast in Plaque Psoriasis, sponsored by Alumis Inc. Completed at 156 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Alumis Inc · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Aug 2026.
Updated Oct 28, 20264 sites added4 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
912
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.

Enrollment
37th of 673
912 · median 77
Started
2024
with 15 others
Phase 3
188 of 764
6 open now
Registered
718th of 764
by date

Among the 764 studies in Psoriasis with a site in United States, this one is the 37th largest by enrollment of the 673 interventional ones that give a count, is one of 16 that started in 2024, is one of 188 in phase 3, and was the 718th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 764 studies in Psoriasis with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are:

  • Does ESK-001 reduce the severity of people's psoriasis?
  • How safe is ESK-001 in people with moderate to severe plaque psoriasis?

The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psoriasis).

People taking part in this study must be men or women aged at least 18 years and have had plaque psoriasis for at least 6 months, currently moderate to severe.

Participants will:

  • take drug every day for 24 weeks.
  • visit the clinic for checkups and tests.
  • fill out questionnaires about their psoriasis, itch severity, and change in quality of life.
  • be assessed for health issues and side effects, physical examinations, vital signs, heart electrical activity measurements, and psychological health.
  • provide blood and urine samples.
03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females, age ≥18 years
  2. Diagnosis of plaque psoriasis for ≥6 months
  3. Plaques covering ≥10% of BSA
  4. PASI ≥12
  5. sPGA ≥3
  6. Women of (WOCBP) and males who are sexually active with WOCBP must agree to adhere to highly effective methods of

Exclusion criteria

Exclusion Criteria:

  1. Nonplaque psoriasis or other inflammatory skin conditions
  2. immune-mediated conditions commonly associated with psoriasis (eg inflammatory bowel disease). Participants with psoriatic arthritis may participate
  3. Pregnant, lactating, or planning to get pregnant during the study
  4. Use of drugs prior to Study Day 1 that treat or may affect psoriasis:

    • Topical within 2 weeks
    • Phototherapy or any systemic treatments within 4 weeks
    • Any biologic agent targeted to IL-12 or IL-23 within 6 months, oral IL-12 or IL-23 or TNFα inhibitor within 2 months, or IL-17 within 4 months
    • Systemic or immunomodulatory drugs within 4 weeks
    • Modulators of B cells within 6 months, or T cells within 3 months
    • JAK inhibitors or TYK2 inhibitors within 4 weeks
    • PDE4 inhibitor within 2 months
    • Any agent, within 30 days or 5 half-lives or is currently enrolled in an investigational study
  5. Lack of clinical response to a TYK2, IL-12, or IL-23 targeted psoriasis treatment
  6. Participants with >450 msec (males) or >470 msec (females) at Screening
  7. Unstable cardiovascular disease, defined as a recent clinical deterioration or a cardiac hospitalization within the last 3 months
  8. Evidence of recent or recurrent herpes zoster or herpes simplex viral infection
  9. Evidence of active infection or positive test result for , , or TB
  10. History of serious bacterial, fungal, or viral infections that led to hospitalization, or any recent serious infection requiring antibiotic treatment
  11. Any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status
  12. Lab abnormalities indicating significant renal, hepatic or bone marrow dysfunction
  13. History of any immune-mediated or inflammatory medical condition for which participants requires current systemic

    * Stable doses of inhaled corticosteroids for treatment of asthma are allowed

  14. Known current or current evaluation for a potential malignancy or history of malignancy within the past 5 years prior to screening, except for adequately treated basal cell or squamous cell skin carcinoma or carcinoma in situ of the cervix
  15. within 4 weeks prior to Study Day 1
  16. Participant has planned surgery during the study period
  17. Any acute or chronic illness/condition or evidence of an unstable clinical condition that, in the opinion of the Investigator, will substantially increase the risk to the participant if he or she participates in the study
  18. History of mental illness within the last 5 years, unless receiving a fixed regimen of psychiatric medications for at least 6 months before screening or has not required or been prescribed any psychiatric medication within 12 months before screening
  19. Evidence of severe depressive symptoms or active suicidal ideation or behavior
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
912 participants (actual)

Study arms

  • Experimental
    ESK-001

    ESK-001 administered as an oral tablet

    Drug: Envudeucitinib

  • Placebo comparator
    Placebo

    Matching oral placebo

    Drug: Placebo

  • Active comparator
    Apremilast

    Apremilast administered as an oral capsule

    Drug: Apremilast

Interventions

06

What researchers measure

Primary outcomes

  1. To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo

    Proportion of participants achieving ≥75% reduction in PASI score. Proportion of participants achieving a score of 0 or 1 on sPGA.

    Time frame: 16 weeks

Secondary outcomes

  1. To compare the Psoriasis Area and Severity Index (PASI-90 and PASI-100) between ESK-001 and placebo or apremilast

    Proportion of participants achieving of ≥90% or 100% reduction in PASI

    Time frame: 24 weeks

  2. To compare the Psoriasis Area and Severity Index (PASI-75) between ESK-001 and apremilast

    Proportion of participants achieving of ≥75% reduction in PASI

    Time frame: 24 weeks

  3. To compare the Static Physician's Global Assessment (sPGA-0/1) between ESK-001 and apremilast

    Proportion of participants achieving a score of 0 or 1 on sPGA

    Time frame: 24 weeks

  4. To compare the affected body surface area (%BSA) between ESK-001 and placebo or apremilast

    Change from baseline in %BSA

    Time frame: 24 weeks

  5. To compare the scalp specific Physician's Global Assessment (ssPGA) between ESK-001 and placebo or apremilast.

    Proportion of participants achieving a score of 0 or 1 on ssPGA

    Time frame: 24 weeks

  6. To compare the Psoriasis Symptoms and Signs Diary (PSSD) between ESK-001 and placebo or apremilast

    Proportion of participants achieving a score of 0

    Time frame: 24 weeks

  7. To compare the Dermatology Life Quality Index (DLQI) between ESK-001 and placebo or apremilast

    Proportion of participants achieving a score of 0 or 1

    Time frame: 24 weeks

  8. To compare the Pruritus numeric rating scale (NRS) between ESK-001 and placebo

    Change from baseline in Pruritus NRS

    Time frame: 24 weeks

  9. Proportion of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Time frame: 24 weeks

  10. To characterize the pharmacokinetics of ESK-001

    Maximum \[Cmax\] and minimum \[Cmin\] plasma concentration

    Time frame: 24 weeks

07

Study locations

156 sites
  • Alliance Dermatology
    Phoenix, Arizona 85032, United States
  • Scottsdale Clinical Trials
    Scottsdale, Arizona 85260, United States
  • Northwest Arkansas Clinical Trials Center (NWACTC), PLLC
    Rogers, Arkansas 72758-8600, United States
  • Exalt Clinical Research
    Chula Vista, California 91910, United States
  • California Dermatology & Clinical Research Institute
    Encinitas, California 92024-7700, United States
  • First OC Dermatology Research Inc
    Fountain Valley, California 92708, United States
  • Marvel Clinical Research, LLC
    Huntington Beach, California 92647, United States
  • Sunwise Clinical Research, LLC
    Lafayette, California 94549, United States
  • Wallace Medical Group Inc
    Los Angeles, California 90056, United States
  • Northridge Clinical Trials - Elite Clinical Network
    Northridge, California 91325, United States
  • Pasadena Clinical Trials
    Pasadena, California 91101, United States
  • Therapeutics Clinical Research
    San Diego, California 92123, United States
  • Unison Clinical Trials/ Shahram Jacobs MD
    Sherman Oaks, California 91403-1814, United States
  • Olive View - UCLA Education & Research Institute
    Sylmar, California 91342, United States
  • California Dermatology Institute - Thousand Oaks
    Thousand Oaks, California 91320-2130, United States
  • Clearlyderm Dermatology - West Boca Raton
    Boca Raton, Florida 33428, United States
  • Driven Clinical Research
    Coral Gables, Florida 33134, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Glick Skin Institute - Margate
    Margate, Florida 33063-7011, United States
  • San Marcus Research Clinic, Inc - Miami
    Miami Lakes, Florida 33014, United States
  • Savin Medical Group LLC
    Miami Lakes, Florida 33014, United States
  • Oceanic Research Group
    North Miami Beach, Florida 33169, United States
  • LENUS Research
    Sweetwater, Florida 33172, United States
  • Caban Skin Institute
    Tampa, Florida 33607, United States
  • ForCare Medical Center
    Tampa, Florida 33613-1244, United States
  • Skin Care Physicians of Georgia - Warner Robins
    Macon, Georgia 31217, United States
  • MetroMed Clinical Trials
    Chicago, Illinois 60614-3625, United States
  • Arlington Dermatology
    Rolling Meadows, Illinois 60008, United States
  • NorthShore Medical Group - Dermatology - Skokie
    Skokie, Illinois 60077-1049, United States
  • Dundee Dermatology
    West Dundee, Illinois 60118, United States
  • Dawes Fretzin Clinical Research Group
    Columbus, Indiana 47201, United States
  • The South Bend Clinic
    South Bend, Indiana 46617, United States
  • Equity Medical - Bowling Green
    Bowling Green, Kentucky 42104, United States
  • Velocity Clinical Research at The Dermatology Clinic, Baton Rouge
    Baton Rouge, Louisiana 70808, United States
  • Tulane University School of Medicine
    New Orleans, Louisiana 70112, United States
  • MetroBoston Clinical Partners
    Brighton, Massachusetts 02135, United States
  • Cleaver Dermatology
    Kirksville, Missouri 63501-5362, United States
  • OptiSkin
    New York, New York 10128-0724, United States
  • The Ohio State University Wexner Medical Center (OSUWMC) - OSU Dermatology East - Columbus
    Gahanna, Ohio 43230-5317, United States
  • Dermatologists of Southwestern Ohio, LLC
    Mason, Ohio 45040-4520, United States
  • Unity Clinical Research (UCR)
    Oklahoma City, Oklahoma 73118, United States
  • Velocity Clinical Research, Medford
    Medford, Oregon 97504, United States
  • Oregon Medical Research Center
    Portland, Oregon 97201, United States
  • Paddington Testing Company Inc.
    Philadelphia, Pennsylvania 19103, United States
  • UPMC Department of Dermatology
    Pittsburgh, Pennsylvania 15213, United States
  • Health Concepts
    Rapid City, South Dakota 57702-9208, United States
  • Discover Dermatology, LLC d/b/a Goodlettsville Dermatology Research
    Goodlettsville, Tennessee 37072-2301, United States
  • Discover Dermatology, LLC d/b/a Cumberland Skin Center for Clinical Research under Objective Health
    Hermitage, Tennessee 37076, United States
  • UT Health Houston Department of Dermatology
    Bellaire, Texas 77401, United States
  • Studies in Dermatology, LLC
    Cypress, Texas 77429, United States
  • Reveal Research Institute
    Frisco, Texas 75033, United States
  • Center for Clinical Studies - Texas Medical Center
    Houston, Texas 77004, United States
  • Austin Institute for Clinical Research - Houston
    Houston, Texas 77056, United States
  • University of Utah Health Care - Midvalley Health Center
    Murray, Utah 84107, United States
  • Frontier Dermatology
    Mill Creek, Washington 98012, United States
  • Premier Specialists
    Kogarah, New South Wales 2217, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • North Eastern Health Specialists (NEHS)
    Campbelltown, South Australia 5074, Australia
  • Skin Health Institute Inc.
    Carlton, Victoria 3053, Australia
  • Sinclair Dermatology
    East Melbourne, Victoria 3002, Australia
  • Multiprofile Hospital for Active Treatment Dr Tota Venkova
    Gabrovo, 5300, Bulgaria
  • Medikal Center Kordis
    Pleven, 5800, Bulgaria
  • Skin and Venereal Diseases Center EOOD
    Sofia, 1404, Bulgaria
  • Diagnostic Consultative Center Aleksandrovska EOOD
    Sofia, 1431, Bulgaria
  • Clineca
    Stara Zagora, 6000, Bulgaria
  • Rejuvenation Medical Group Edmonton Downtown
    Edmonton, Alberta T5J 3S9, Canada
  • Enverus Medical Research
    Surrey, British Columbia V3V 0C6, Canada
  • Dermatrials Research Inc.
    Hamilton, Ontario L8N 1Y2, Canada
  • Centricity Research
    London, Ontario N6A 2C2, Canada
  • DermEffects
    London, Ontario N6H 5L5, Canada
  • Lynderm Research Inc.
    Markham, Ontario L3P 1X3, Canada
  • DermEdge Research
    Mississauga, Ontario L4Y 4C5, Canada
  • Institute of Cosmetic & Laser Surgery
    Oakville, Ontario L6J 7W5, Canada
  • The Centre for Dermatology
    Richmond Hill, Ontario L4B 1A5, Canada
  • North York Research Inc.
    Toronto, Ontario M2N3A6, Canada
  • Canadian Dermatology Centre
    Toronto, Ontario M3B 0A7, Canada
  • Dermatology on Bloor
    Toronto, Ontario M4W 2N4, Canada
  • Alliance Clinical Trials
    Waterloo, Ontario N2J 1C4, Canada
  • "Centre de Recherche Dermatologique du Quebec Metropolitain Inc."
    Québec, Quebec G1V 4X7, Canada
  • Dermatologie Sima Inc.
    Verdun, Quebec H4G 3E7, Canada
  • Fakultni nemocnice Plzen Dermatovenerologicka klinika
    Pilsen, Bory 301 00, Czechia
  • Pratia Brno s.r.o.
    Brno, Moravia 60200, Czechia
  • Dermskin, s.r.o.
    Olomouc, Moravia 77900, Czechia
  • Kozni ambulance Kutna Hora, s.r.o.
    Kutná Hora, 28401, Czechia
  • DERMAMEDICA, s.r.o.
    Náchod, 54701, Czechia
  • Nemocnice Nový Jičín, A.S.
    Nový Jičín, 74101, Czechia
  • CCR Ostrava, s.r.o.
    Ostrava, 70200, Czechia
  • Vesalion sro
    Ostrava, 70200, Czechia
  • Pratia Pardubice a.s.
    Pardubice, 53002, Czechia
  • Clintrial s.r.o.
    Prague, 100 00, Czechia
  • Fakultni Nemocnice Kralovske Vinohrady FNKV Dermatovenerologicka Klinika
    Prague, 10034, Czechia
  • Sanatorium Profesora Arenbergera
    Prague, 110 00, Czechia
  • Pratia Prague, s.r.o.
    Prague, 13000, Czechia
  • Praglandia
    Prague, 15000, Czechia
  • Dermatologicka ambulance - Svitavy
    Svitavy, 568 02, Czechia
  • MUDr Radka Neumannova
    Svitavy, 56802, Czechia
  • Eberhard Karls Universitaet Tuebingen Universitaets Hautklinik Tuebingen
    Tübingen, Baden-Wurttemberg 72070, Germany
  • Hautarztpraxis Dr. Mihaescu
    Augsburg, Bavaria 86150, Germany
  • Hautarztpraxis Mahlow
    Mahlow, Brandenburg 15831, Germany
  • Universitatsklinikum Frankfurt
    Frankfurt am Main, Hesse 60590, Germany

Showing the first 100 of 156 sites across 10 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Undecided — The Sponsor Alumis Inc. is a clinical-stage biopharmaceutical company that has not yet adopted an Individual Participant Data (IPD) sharing plan.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Sep 2025, 13 months.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 13 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2024
First posted
Sep 19, 2024
StartActual
Jul 25, 2024
Primary completionActual
Sep 19, 2025
CompletionActual
Nov 20, 2025
Results delay requested
Aug 6, 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 4 sites removed
Show 4 added (2 Bulgaria, 2 Portugal)
  • Multiprofile Hospital for Active Treatment Dr Tota Venkova · Gabrovo, Bulgaria
  • Clineca · Stara Zagora, Bulgaria
  • Hospital CUF Descobertas · Lisbon, Portugal
  • Unidade Local de Saude Santo Antonio Hospital de Santo Antonio · Porto, Portugal
Show 4 removed
  • Multiprofile Hospital for Active Treatment Dr Tota Venkova · Gabrovo, Bulgaria
  • Clineca · Stara Zagora, Bulgaria
  • Hospital CUF Descobertas · Lisbon, Portugal
  • Unidade Local de Saude Santo Antonio Hospital de Santo Antonio · Porto, Portugal
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    4 sites added, 4 sites removed
    Show 4 added (2 Bulgaria, 2 Portugal)
    • Multiprofile Hospital for Active Treatment Dr Tota Venkova · Gabrovo, Bulgaria
    • Clineca · Stara Zagora, Bulgaria
    • Hospital CUF Descobertas · Lisbon, Portugal
    • Unidade Local de Saude Santo Antonio Hospital de Santo Antonio · Porto, Portugal
    Show 4 removed
    • Multiprofile Hospital for Active Treatment Dr Tota Venkova · Gabrovo, Bulgaria
    • Clineca · Stara Zagora, Bulgaria
    • Hospital CUF Descobertas · Lisbon, Portugal
    • Unidade Local de Saude Santo Antonio Hospital de Santo Antonio · Porto, Portugal
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06586112
Lead sponsor
Alumis Inc
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Jul 25, 2024
Primary completion
Sep 19, 2025
Completion
Nov 20, 2025
Last update
Oct 28, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Envudeucitinib

Start the discussion